Operating Income (Loss) in USD of ELITE PHARMACEUTICALS INC /NV/ from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly/annual Operating Income (Loss) history and change rate from Q2 2010 to Q3 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Operating Income (Loss) for the quarter ending 30 Sep 2025 was $8.21M, a 136% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ Operating Income (Loss) for the twelve months ending 30 Sep 2025 was $42.2M, a 189% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Operating Income (Loss) for 2024 was $19.6M, a 81.7% increase from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Operating Income (Loss) for 2023 was $10.8M, a 193% increase from 2022.
  • ELITE PHARMACEUTICALS INC /NV/ annual Operating Income (Loss) for 2022 was $3.68M, a 27.5% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $42.2M $8.21M +$4.73M +136% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 $37.4M $21.7M +$17.8M +462% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $19.6M $11.2M +$7.43M +199% 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025
Q4 2024 $12.2M $1.1M -$2.43M -68.9% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025
Q3 2024 $14.6M $3.48M +$1.56M +81% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 $13.1M $3.86M +$2.26M +141% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 $10.8M $3.73M +$4.12M 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025
Q4 2023 $6.67M $3.53M +$1.57M +80.3% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025
Q3 2023 $5.1M $1.93M +$844K +78.1% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 $4.26M $1.6M +$579K +56.6% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 $3.68M -$387K -$1.24M -145% 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024
Q4 2022 $4.91M $1.96M +$128K +6.98% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024
Q3 2022 $4.79M $1.08M -$341K -24% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $5.13M $1.02M +$57.5K +5.96% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 $5.07M $852K +$1.92M 01 Jan 2022 31 Mar 2022 10-K 29 Jun 2023
Q4 2021 $3.15M $1.83M +$830K +82.9% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023
Q3 2021 $2.32M $1.42M +$82.3K +6.14% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 $2.24M $965K +$135K +16.2% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 $2.1M -$1.07M +$307K +22.3% 01 Jan 2021 31 Mar 2021 10-K 29 Jun 2022
Q4 2020 $1.8M $1M +$310K +44.8% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022
Q3 2020 $1.49M $1.34M +$1.79M 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$307K $831K +$1.98M 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021
Q1 2020 -$2.29M -$1.37M +$636K +31.6% 01 Jan 2020 31 Mar 2020 10-K 14 Jun 2021
Q4 2019 -$2.92M $691K +$3.33M 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021
Q3 2019 -$6.25M -$455K +$2.2M +82.9% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020
Q2 2019 -$8.45M -$1.15M +$711K +38.2% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020
Q1 2019 -$9.16M -$2.01M +$613K +23.4% 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020
Q4 2018 -$9.77M -$2.64M -$578K -28.1% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020
Q3 2018 -$9.19M -$2.65M -$523K -24.6% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019
Q2 2018 -$8.67M -$1.86M +$380K +17% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 -$9.05M -$2.62M +$567K +17.8% 01 Jan 2018 31 Mar 2018 10-K 14 Jun 2018
Q4 2017 -$9.62M -$2.06M -$337K -19.6% 01 Oct 2017 31 Dec 2017 10-Q 11 Feb 2019
Q3 2017 -$9.28M -$2.13M -$925K -76.8% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018
Q2 2017 -$8.36M -$2.24M -$1M -80.8% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 -$7.36M -$3.19M -$3.76M -659% 01 Jan 2017 31 Mar 2017 10-K 14 Jun 2018
Q4 2016 -$3.59M -$1.72M +$991K +36.5% 01 Oct 2016 31 Dec 2016 10-K 14 Jun 2018
Q3 2016 -$4.59M -$1.21M +$2.56M +68% 01 Jul 2016 30 Sep 2016 10-K 14 Jun 2018
Q2 2016 -$7.15M -$1.24M +$1.17M +48.6% 01 Apr 2016 30 Jun 2016 10-K 14 Jun 2018
Q1 2016 -$8.32M $571K +$6.03M 01 Jan 2016 31 Mar 2016 10-K 14 Jun 2018
Q4 2015 -$14.3M -$2.71M -$156K -6.1% 01 Oct 2015 31 Dec 2015 10-K 14 Jun 2018
Q3 2015 -$14.2M -$3.77M +$294K +7.24% 01 Jul 2015 30 Sep 2015 10-K 14 Jun 2018
Q2 2015 -$14.5M -$2.41M +$2.02M +45.7% 01 Apr 2015 30 Jun 2015 10-K 14 Jun 2018
Q1 2015 -$16.5M -$5.46M -$3.07M -129% 01 Jan 2015 31 Mar 2015 10-K 14 Jun 2017
Q4 2014 -$13.4M -$2.56M -$1.32M -107% 01 Oct 2014 31 Dec 2014 10-K 14 Jun 2017
Q3 2014 -$12.1M -$4.06M -$3.37M -491% 01 Jul 2014 30 Sep 2014 10-K 14 Jun 2017
Q2 2014 -$8.74M -$4.43M -$3.46M -354% 01 Apr 2014 30 Jun 2014 10-K 14 Jun 2017
Q1 2014 -$5.28M -$2.38M -$2.1M -728% 01 Jan 2014 31 Mar 2014 10-K 15 Jun 2016
Q4 2013 -$3.19M -$1.24M -$963K -351% 01 Oct 2013 31 Dec 2013 10-K 15 Jun 2016
Q3 2013 -$2.23M -$687K -$172K -33.3% 01 Jul 2013 30 Sep 2013 10-K 15 Jun 2016
Q2 2013 -$2.05M -$976K -$490K -101% 01 Apr 2013 30 Jun 2013 10-K 15 Jun 2016
Q1 2013 -$1.56M -$288K +$319K +52.6% 01 Jan 2013 31 Mar 2013 10-K 30 Jun 2014
Q4 2012 -$1.88M -$274K +$157K +36.4% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014
Q3 2012 -$2.04M -$515K +$76.3K +12.9% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013
Q2 2012 -$2.12M -$486K -$149K -44.3% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 -$1.97M -$607K +$118K +16.3% 01 Jan 2012 31 Mar 2012 10-K 21 Jun 2013
Q4 2011 -$2.08M -$431K -$504K -691% 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013
Q3 2011 -$1.58M -$592K -$455K -332% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012
Q2 2011 -$1.13M -$337K -$240K -248% 01 Apr 2011 30 Jun 2011 10-Q 14 Aug 2012
Q1 2011 -$886K -$725K 01 Jan 2011 31 Mar 2011 10-K 29 Jun 2012
Q4 2010 $72.9K 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012
Q3 2010 -$137K 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011
Q2 2010 -$96.8K 01 Apr 2010 30 Jun 2010 10-Q/A 19 Aug 2011

ELITE PHARMACEUTICALS INC /NV/ Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $19.6M +$8.81M +81.7% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025
2023 $10.8M +$7.11M +193% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025
2022 $3.68M -$1.39M -27.5% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024
2021 $5.07M +$2.97M +141% 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023
2020 $2.1M +$4.39M 01 Apr 2020 31 Mar 2021 10-K 29 Jun 2022
2019 -$2.29M +$6.87M +75% 01 Apr 2019 31 Mar 2020 10-K 14 Jun 2021
2018 -$9.16M -$107K -1.19% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020
2017 -$9.05M -$1.7M -23% 01 Apr 2017 31 Mar 2018 10-K 21 Jun 2019
2016 -$7.36M +$961K +11.6% 01 Apr 2016 31 Mar 2017 10-K 14 Jun 2018
2015 -$8.32M +$8.19M +49.6% 01 Apr 2015 31 Mar 2016 10-K 14 Jun 2018
2014 -$16.5M -$11.2M -212% 01 Apr 2014 31 Mar 2015 10-K 14 Jun 2017
2013 -$5.28M -$3.72M -238% 01 Apr 2013 31 Mar 2014 10-K 15 Jun 2016
2012 -$1.56M +$403K +20.5% 01 Apr 2012 31 Mar 2013 10-K 30 Jun 2014
2011 -$1.97M -$1.08M -122% 01 Apr 2011 31 Mar 2012 10-K 21 Jun 2013
2010 -$886K 01 Apr 2010 31 Mar 2011 10-K 29 Jun 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.